Vor Biopharma
Yahoo Finance • last year
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JM... Full story
Yahoo Finance • last year
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to date All three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor Bio’s approachConference call today, N... Full story
Yahoo Finance • last year
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11Three oral abstracts and two poster presentations accepted at ASH 2023 Dec 9-12 CAMBRIDGE, Mass., Nov. 07, 2... Full story
Yahoo Finance • last year
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of October 30, 2023, the Compensation Committee of the Board of Directors... Full story
Yahoo Finance • last year
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Stifel 2023 Health... Full story
Yahoo Finance • last year
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
Three oral and two poster presentations accepted by ASH Company to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and Chief of the Hematologic Malignancies Pr... Full story
Yahoo Finance • 2 years ago
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
Patients transplanted with trem-celachievedprimary neutrophil engraftment and high levels of myeloid donor chimerism. Strong investigator enthusiasm and continued robust enrollment; additional data updates expected by year-end 2023.U.S. FD... Full story
Yahoo Finance • 2 years ago
Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
Initial clinical data supports founding vision that engineered hematopoietic stem cells can enable treatment options after AML transplant Additional trem-cel data expected by year-end 2023; VCAR33ALLO on track for IND submission in first h... Full story
Yahoo Finance • 2 years ago
5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science
SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis i... Full story
Yahoo Finance • 2 years ago
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, ope... Full story
Yahoo Finance • 2 years ago
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference
CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities’ 3rd Annual Oncology Confere... Full story
Yahoo Finance • 2 years ago
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
Initial clinical data for VOR33 on track for Q4 2022 Eyal C. Attar, M.D. appointed as Chief Medical OfficerInitiated in-house clinical manufacturing at Cambridge, MA headquarters CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vor B... Full story
Yahoo Finance • 2 years ago
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief Medical Officer (CMO). Dr. Attar bring... Full story
Yahoo Finance • 2 years ago
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term engraftment and persistence of editing -Data presented at European Society of Gene & Cell Therapy (ESGCT) Ann... Full story
Yahoo Finance • 2 years ago
Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update
Initial clinical data for patients treated with Vor Bio’s engineered HSC candidate VOR33 on track for Q4 2022In-house manufacturing facility in Cambridge, MA operational in Q4 2022Data presented at EHA successfully demonstrates in-vivo eng... Full story
Yahoo Finance • 3 years ago
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for treatment of acute myeloid leukemia Dual edited hematopoietic stem and progenitor cells... Full story
Yahoo Finance • 3 years ago
Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022Data presented at Keystone Symposia demonstrates significant advancement of novel multiplex editing platformIn-house manufacturing facility in Cambridge,... Full story
Yahoo Finance • 3 years ago
Vor to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating virtually in two upcom... Full story
Yahoo Finance • 3 years ago
Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that two abstracts have been accepted for poster presentations at the Keystone Symposia Pre... Full story
Yahoo Finance • 3 years ago
Vor Bio Announces Retirement of Chief Medical Officer
CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Christopher Slapak, Chief Medical Officer for Vor Bio plans to retire. The Vor Bio... Full story
